Taysha IPO Presentation Deck
Our strategic partnership with UTSW
We have access to a world-class team of scientists and cutting-edge
technology through an exclusive, worldwide royalty-free license to
discover, develop, and commercialize gene therapies led by:
Berge Minassian, MD, Division Chief of Child Neurology
Pediatric neurologist with expertise in neurodegenerative diseases,
neurodevelopmental disorders, and genetic forms of epilepsy
Discovered MECP2 CNS isoform (Rett syndrome)
Steven Gray, PhD, Director of Viral Vector Core, Associate Professor Dept of Peds
AAV-based vector engineering expertise and optimizing CNS delivery of transgenes
Administered the first AAV9-based therapy to patients via intrathecal route
Exclusive access to a flexible, scalable, and well-characterized GMP manufacturing suite that
utilizes a suspension HEK293 process
- Exclusive access to next generation platform technologies, including novel redosing
platform, transgene regulation (miRARE), and capsid development
UT Southwestern
Medical Center
13View entire presentation